ONC010ᵀᴹ
The Next Generation Drug Formulation
Our 100% licensed proprietary lead drug candidate, utilizes Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor technology.
Our 100% licensed proprietary lead drug candidate, utilizes Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor technology.
Our 100% licensed proprietary lead drug candidate, utilizes Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor technology.
Preclinical studies have shown PNKP inhibitor to be effective against multiple cancers & synergizes with tumor-suppressing genes (SHP-11, PTEN2). There are 5 Patents protecting PKNP technology and ONC010™, ensuring market exclusivity.
Preclinical studies have shown PNKP inhibitor to be effective against multiple cancers & synergizes with tumor-suppressing genes (SHP-11, PTEN2). There are 5 Patents protecting PKNP technology and ONC010™, ensuring market exclusivity.
Preclinical studies have shown PNKP inhibitor to be effective against multiple cancers & synergizes with tumor-suppressing genes (SHP-11, PTEN2). There are 5 Patents protecting PKNP technology and ONC010™, ensuring market exclusivity.
Future Expansion
Foundation for oncology advancements beyond colorectal cancer, such as GBM (Glioblastoma multiforme) and ovarian cancer.
Future Expansion
Foundation for oncology advancements beyond colorectal cancer, such as GBM (Glioblastoma multiforme) and ovarian cancer.
Future Expansion
Foundation for oncology advancements beyond colorectal cancer, such as GBM (Glioblastoma multiforme) and ovarian cancer.
Future Expansion
Foundation for oncology advancements beyond colorectal cancer, such as GBM (Glioblastoma multiforme) and ovarian cancer.
Cancer-Targeted Approach
Proprietary Formula: Aims to prevent DNA repair to eliminate cancer cells
Enhanced Delivery: Nanoparticles ensure precision targeting
Optimized Results: Designed to work with chemo/radiation/surgery to potentially improve outcomes and reduce side effects
Cancer-Targeted Approach
Proprietary Formula: Aims to prevent DNA repair to eliminate cancer cells
Enhanced Delivery: Nanoparticles ensure precision targeting
Optimized Results: Designed to work with chemo/radiation/surgery to potentially improve outcomes and reduce side effects
Cancer-Targeted Approach
Proprietary Formula: Aims to prevent DNA repair to eliminate cancer cells
Enhanced Delivery: Nanoparticles ensure precision targeting
Optimized Results: Designed to work with chemo/radiation/surgery to potentially improve outcomes and reduce side effects
Cancer-Targeted Approach
Proprietary Formula: Aims to prevent DNA repair to eliminate cancer cells
Enhanced Delivery: Nanoparticles ensure precision targeting
Optimized Results: Designed to work with chemo/radiation/surgery to potentially improve outcomes and reduce side effects
Key Advantages
Scalable across multiple cancer types
Supported by 5 patents safeguarding innovation and market leadership
Key Advantages
Scalable across multiple cancer types
Supported by 5 patents safeguarding innovation and market leadership
Key Advantages
Scalable across multiple cancer types
Supported by 5 patents safeguarding innovation and market leadership
Key Advantages
Scalable across multiple cancer types
Supported by 5 patents safeguarding innovation and market leadership
Colorectal Drug Success
Preclinical Validation
Tumor Reduction and Survival Impact
Tumor Reduction and Survival Impact
Existing Results in Animal Models
Existing Results in Animal Models
Figure 1
Figure 1
Studies revealed NP/A83B4C63, Onco's novel nanoparticle formulation, demonstrated a noticeable increase in median survival time of 60 days, compared to 23 days in untreated mice with PTEN-deficient colorectal cancer (CRC).¹
Studies revealed NP/A83B4C63, Onco's novel nanoparticle formulation, demonstrated a noticeable increase in median survival time of 60 days, compared to 23 days in untreated mice with PTEN-deficient colorectal cancer (CRC).¹
Studies revealed NP/A83B4C63, Onco's novel nanoparticle formulation, demonstrated a noticeable increase in median survival time of 60 days, compared to 23 days in untreated mice with PTEN-deficient colorectal cancer (CRC).¹
Figure 2
Figure 2
Compared to placebo, NP/A83B4C63 showcased solid performance, reducing tumor growth.²
Compared to placebo, NP/A83B4C63 showcased solid performance, reducing tumor growth.²
Compared to placebo, NP/A83B4C63 showcased solid performance, reducing tumor growth.²
Path to Regulatory Approval
A regulatory roadmap for PKNP drug candidates
A regulatory roadmap for PKNP drug candidates
A regulatory roadmap for PKNP drug candidates
Validated Preclinical Data
Preclinical studies confirm both safety and efficacy, establishing a strong foundation for regulatory submissions and clinical trials.
Validated Preclinical Data
Preclinical studies confirm both safety and efficacy, establishing a strong foundation for regulatory submissions and clinical trials.
Validated Preclinical Data
Preclinical studies confirm both safety and efficacy, establishing a strong foundation for regulatory submissions and clinical trials.
Validated Preclinical Data
Preclinical studies confirm both safety and efficacy, establishing a strong foundation for regulatory submissions and clinical trials.
Regulatory Milestones
FDA submission targeted for 2025/26, with Phase I trials anticipated to begin in 2026, focusing on safety and dosage.
Regulatory Milestones
FDA submission targeted for 2025/26, with Phase I trials anticipated to begin in 2026, focusing on safety and dosage.
Regulatory Milestones
FDA submission targeted for 2025/26, with Phase I trials anticipated to begin in 2026, focusing on safety and dosage.
Regulatory Milestones
FDA submission targeted for 2025/26, with Phase I trials anticipated to begin in 2026, focusing on safety and dosage.
Fast-Track Eligibility
Oncology therapies addressing high unmet needs increase the likelihood of expedited regulatory reviews, such as Fast-Track Designation.
Fast-Track Eligibility
Oncology therapies addressing high unmet needs increase the likelihood of expedited regulatory reviews, such as Fast-Track Designation.
Fast-Track Eligibility
Oncology therapies addressing high unmet needs increase the likelihood of expedited regulatory reviews, such as Fast-Track Designation.
Fast-Track Eligibility
Oncology therapies addressing high unmet needs increase the likelihood of expedited regulatory reviews, such as Fast-Track Designation.
Global Multi-Region Strategy
Plans include submissions to the FDA, EMA, and Asia-Pacific regulatory agencies to maximize international market reach.
Global Multi-Region Strategy
Plans include submissions to the FDA, EMA, and Asia-Pacific regulatory agencies to maximize international market reach.
Global Multi-Region Strategy
Plans include submissions to the FDA, EMA, and Asia-Pacific regulatory agencies to maximize international market reach.
Global Multi-Region Strategy
Plans include submissions to the FDA, EMA, and Asia-Pacific regulatory agencies to maximize international market reach.
References
Sadat et al. A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer. J Control Release. 2021 Jun 10;334:335-352. doi:10.1016/j.jconrel.2021.04.034. https://www.sciencedirect.com/science/article/pii/S016836592100208X?via%3Dihub
Sadat et al. A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer. J Control Release. 2021 Jun 10;334:335-352. doi:10.1016/j.jconrel.2021.04.034. https://www.sciencedirect.com/science/article/pii/S016836592100208X?via%3Dihub
Reach Us
1309 – 7th Street SW
Calgary, Alberta, Canada
T2R 1A5
investors@oncoinnovations.com
+1 (888) 261–8055
© 2025 Onco-Innovations Limited | All Rights Reserved
Reach Us
1309 – 7th Street SW
Calgary, Alberta, Canada
T2R 1A5
investors@oncoinnovations.com
+1 (888) 261–8055
© 2025 Onco-Innovations Limited | All Rights Reserved
Reach Us
1309 – 7th Street SW
Calgary, Alberta, Canada
T2R 1A5
investors@oncoinnovations.com
+1 (888) 261–8055
© 2025 Onco-Innovations Limited | All Rights Reserved
Reach Us
1309 – 7th Street SW
Calgary, Alberta, Canada
T2R 1A5
investors@oncoinnovations.com
+1 (888) 261–8055
© 2025 Onco-Innovations Limited | All Rights Reserved